Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP

BACKGROUND: Patients with carcinoma of unknown primary (CUP) have a dismal prognosis, even when treated with multi-agent chemotherapy. We hypothesised that adding the epidermal growth-factor receptor (EGFR) inhibitor cetuximab to standard first-line chemotherapy with paclitaxel and carboplatin would...

Descripción completa

Detalles Bibliográficos
Autores principales: Folprecht, Gunnar, Trautmann, Karolin, Stein, Alexander, Huebner, Gerdt, Stahl, Michael, Kasper, Stefan, Kretzschmar, Albrecht, Köhne, Claus-Henning, Grünwald, Viktor, Hofheinz, Ralf-Dieter, Schütte, Katharina, Löffler, Harald, Bokemeyer, Carsten, Krämer, Alwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884392/
https://www.ncbi.nlm.nih.gov/pubmed/33235314
http://dx.doi.org/10.1038/s41416-020-01141-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884392/
https://www.ncbi.nlm.nih.gov/pubmed/33235314
http://dx.doi.org/10.1038/s41416-020-01141-8

Ejemplares similares